Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million

Reuters03-12

Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million

Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111605BIZWIRE_USPR_____20260311_BW456427) on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618910973?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 04:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618910973","market":"fut","top_or_hot":-1,"title":"Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111605BIZWIRE_USPR_____20260311_BW456427) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 04:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/EVFM\">Evofem Biosciences</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111605BIZWIRE_USPR_____20260311_BW456427) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4584","symbol_name":"避孕概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL7CtcMW:1","article_id":"2618910973","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618910973","pubTimestamp":1773259706,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4584":"避孕概念","BK4007":"制药","EVFM":"Evofem Biosciences, Inc."},"translate_title":"Evofem第四季度净销售额增长35%，达到960万美元，净利润总计280万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVFM":0.9},"content_text":"Evofem Q4 net sales rose 35% to USD 9.6 million as net income totaled USD 2.8 million\n    \n\n        Evofem reported FY 2025 net sales of USD 20.2 million, up 4%, reflecting a higher PHEXX wholesale average cost and a slightly improved gross-to-net ratio, with SOLOSEC also contributing. FY 2025 operating income was USD 3.4 million, and net income attributable to common stockholders was USD 0.3 million, or USD 0.00 per basic and diluted share. Total operating expenses in FY 2025 fell 38% to USD 16.8 million, driven by a USD 5.6 million gain from settling a portion of trade payables and a USD 1.9 million non-cash gain tied to a change in accounting estimates on a contingent royalty liability. In Q4 2025, net sales rose 35% to USD 9.6 million, mainly reflecting higher PHEXX WAC, a more favorable gross-to-net ratio, and higher ex-factory unit sales. Q4 2025 net income was USD 2.8 million, or USD 0.02 per basic and USD 0.00 per diluted share.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111605BIZWIRE_USPR_____20260311_BW456427) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618910973","isCrawlerRequest":true}